Suven Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Thu Apr 09 2026

Suven Pharmaceuticals (NSE: SUVENPHAR) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 1,100 — against a 52-week high of Rs 1,350 and a 1-year return of -14% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 380-420 Cr, with PAT expectations of Rs 168-192 Cr and margin projections of EBITDA 52-56%. This article covers the Suven Pharmaceuticals Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and the most commonly searched investor questions.

Table of Contents

Suven Pharmaceuticals Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Suven Pharmaceuticals has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar:

Company	Results Date	Article
TCS	April 9, 2026	Preview on Univest
Infosys	April 23, 2026	Preview on Univest
Suven Pharmaceuticals	May 2026 (Expected)	This article

Why This Quarter Matters

Suven Pharmaceuticals enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 is the final quarter of FY26 — it determines full-year performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -14%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can sustain recovery momentum.

Suven Pharmaceuticals Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Driver
Revenue	Rs 342 Cr	Rs 380-420 Cr	Volume + pricing
PAT	Rs 152 Cr	Rs 168-192 Cr	Operating leverage
Margin	EBITDA 54.8%	EBITDA 52-56%	Cost control
Key Growth Metric	Q3 trend	10-14% YoY revenue growth	Management execution
Dividend Estimate	—	Rs 10-14 per share	Board recommendation

A positive surprise on any two of the four key parameters — revenue, margin, guidance, and dividend — could drive a meaningful post-results re-rating.

Screen Suven Pharmaceuticals fundamentals on Univest Screener.

5 Key Factors That Will Drive Suven Pharmaceuticals Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 380-420 Cr in Q4 FY26 revenue (Q3: Rs 342 Cr). Q4 is seasonally important for the Pharma/CDMO sector, driven by year-end order execution and government capex push. The ability to convert the pipeline into recognised revenue will be the first test.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 52-56%, versus EBITDA 54.8% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst.

PAT Quality

Net profit is estimated at Rs 168-192 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean, recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue bands, margin targets, and capex plans. In the current global macro environment, credible and specific FY27 guidance will be valued more than usual by the market.

Dividend Declaration

Suven Pharmaceuticals is expected to consider a final dividend of Rs 10-14 per share. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Suven Pharmaceuticals Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty across Indian equities. For Suven Pharmaceuticals, indirect impacts include FII outflows and potential earnings estimate cuts if global demand slows. A tariff negotiation breakthrough remains the most significant macro upside catalyst.

Earnings Miss Risk

If Suven Pharmaceuticals’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus the Rs 380-420 Cr estimate and PAT versus Rs 168-192 Cr as the two primary watchpoints on results day.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling pressure would create headwinds for Suven Pharmaceuticals regardless of company-specific fundamentals.

Sector Regulatory Risk

The Pharma/CDMO sector faces evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Suven Pharmaceuticals’s profitability beyond current consensus models.

Suven Pharmaceuticals Share Price and Analyst Ratings

Suven Pharmaceuticals is trading at Rs 1,100 as of early April 2026, against a 52-week high of Rs 1,350 and a 52-week low of Rs 880. Market cap stands at Rs 28,000 Cr. The 1-year return of -14% reflects sector headwinds alongside company-specific factors.

Brokerage	Rating	Target Price	Thesis
MOFSL	Buy	Rs 1,350	Pharma CDMO; Advent-backed quality
YES Securities	Buy	Rs 1,320	Step-1 API + complex synthesis
JM Financial	Add	Rs 1,250	Client pipeline + capacity expansion
Emkay	Buy	Rs 1,280	Best EBITDA margins mid-cap CDMO

Download the Univest iOS App or Univest Android App to track Suven Pharmaceuticals’s live price and receive real-time Q4 result alerts.

Conclusion

Suven Pharmaceuticals Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma/CDMO sector. Analysts project PAT of Rs 168-192 Cr and revenue of Rs 380-420 Cr. At a CMP of Rs 1,100 and analyst targets ranging from Rs 1,280 to Rs 1,350, the stock offers meaningful risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Suven Pharmaceuticals Q4 results 2026 date?

The Suven Pharmaceuticals Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.

What is the Suven Pharmaceuticals Q4 FY26 PAT estimate?

Analysts estimate Suven Pharmaceuticals Q4 FY26 PAT at Rs 168-192 Cr, based on revenue of Rs 380-420 Cr and margin of EBITDA 52-56%. Actual results may differ from consensus.

What is Suven Pharmaceuticals’s share price ahead of Q4 results?

Suven Pharmaceuticals is trading at Rs 1,100. The 52-week high is Rs 1,350 and low is Rs 880. The 1-year return is -14% and market cap is Rs 28,000 Cr.

Will Suven Pharmaceuticals declare a dividend in Q4 FY26?

Suven Pharmaceuticals is expected to consider a final dividend of Rs 10-14 per share at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Suven Pharmaceuticals?

MOFSL (Buy, Rs 1,350), YES Securities (Buy, Rs 1,320), JM Financial (Add, Rs 1,250), Emkay (Buy, Rs 1,280) have positive ratings heading into Q4 FY26.

What were Suven Pharmaceuticals Q3 FY26 results?

Suven Pharmaceuticals reported Q3 FY26 revenue of Rs 342 Cr and PAT of Rs 152 Cr, with margin at EBITDA 54.8%. These form the baseline for Q4 FY26 estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is Suven Pharmaceuticals a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Suven Pharmaceuticals has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor. Use the Univest Screener to assess fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.